OlympiAD: Further efficacy outcomes in patients with HER2-negative metastatic breast cancer and a germline BRCA mutation receiving olaparib monotherapy vs standard single-agent chemotherapy treatment of physician’s choice

Abstract

Background: The Phase III OlympiAD study (NCT02000622) in patients with metastatic breast cancer (mBC) and a germline BRCA mutation (gBRCAm) showed a statistically significant progression‐free survival (PFS) benefit for olaparib monotherapy over chemotherapy treatment of physician's choice (TPC; hazard ratio [HR] 0.58; 95% CI 0.43, 0.80; P<0.001; 7.0 vs 4.2 months for olaparib vs TPC, respectively). We report further efficacy outcomes for objective response, target lesion shrinkage and tumour burden. Methods: OlympiAD was a randomized, open‐label, Phase III study of olaparib monotherapy vs TPC in HER2‐negative mBC patients with a gBRCAmwho had received =5 weeks [SD] 25.1%; progressive disease [PD] 15.0%) and 28.8% for TPC patients (n=66; CR 1.5%, PR 27.3%, SD 37.9%, PD 33.3%). Median best percentage change from baseline in target lesion size was